scholarly journals T1D exchange quality improvement collaborative: Accelerating change through benchmarking and improvement science for people with type 1 diabetes

2021 ◽  
Author(s):  
Priya Prahalad ◽  
Nicole Rioles ◽  
Nudrat Noor ◽  
Robert Rapaport ◽  
Ruth S. Weinstock ◽  
...  
2021 ◽  
Author(s):  
Ruth S. Weinstock ◽  
Priya Prahalad ◽  
Nicole Rioles ◽  
Osagie Ebekozien

Medical advances, including the development of new medications and advanced technologies, have the potential to improve outcomes for youths and adults with type 1 diabetes, but that potential has not yet been fully realized, particularly in minority groups and those with low socioeconomic status (SES).


2021 ◽  
Author(s):  
Ruth S. Weinstock ◽  
Priya Prahalad ◽  
Nicole Rioles ◽  
Osagie Ebekozien

Medical advances, including the development of new medications and advanced technologies, have the potential to improve outcomes for youths and adults with type 1 diabetes, but that potential has not yet been fully realized, particularly in minority groups and those with low socioeconomic status (SES).


2021 ◽  
pp. cd210028
Author(s):  
Shideh Majidi ◽  
Osagie Ebekozien ◽  
Nudrat Noor ◽  
Sarah K. Lyons ◽  
Ryan McDonough ◽  
...  

2021 ◽  
Author(s):  
Sarah K. Lyons ◽  
Osagie Ebekozien ◽  
Ashley Garrity ◽  
Don Buckingham ◽  
Ori Odugbesan ◽  
...  

Insulin pump therapy in pediatric type 1 diabetes has been associated with better glycemic control than multiple daily injections. However, insulin pump use remains limited. This article describes an initiative from the T1D Exchange Quality Improvement Collaborative aimed at increasing insulin pump use in patients aged 12–26 years with type 1 diabetes from a baseline of 45% in May 2018 to >50% by February 2020. Interventions developed by participating centers included increasing in-person and telehealth education about insulin pump technology, creating and distributing tools to assist in informed decision-making, facilitating insulin pump insurance approval and onboarding processes, and improving clinic staff knowledge about insulin pumps. These efforts yielded a 13% improvement in pump use among the five participating centers, from 45 to 58% over 22 months.


2021 ◽  
pp. cd210027
Author(s):  
Sarah K. Lyons ◽  
Osagie Ebekozien ◽  
Ashley Garrity ◽  
Don Buckingham ◽  
Ori Odugbesan ◽  
...  

2021 ◽  
Author(s):  
Sarah K. Lyons ◽  
Osagie Ebekozien ◽  
Ashley Garrity ◽  
Don Buckingham ◽  
Ori Odugbesan ◽  
...  

Insulin pump therapy in pediatric type 1 diabetes has been associated with better glycemic control than multiple daily injections. However, insulin pump use remains limited. This article describes an initiative from the T1D Exchange Quality Improvement Collaborative aimed at increasing insulin pump use in patients aged 12–26 years with type 1 diabetes from a baseline of 45% in May 2018 to >50% by February 2020. Interventions developed by participating centers included increasing in-person and telehealth education about insulin pump technology, creating and distributing tools to assist in informed decision-making, facilitating insulin pump insurance approval and onboarding processes, and improving clinic staff knowledge about insulin pumps. These efforts yielded a 13% improvement in pump use among the five participating centers, from 45 to 58% over 22 months.


2021 ◽  
pp. 193229682110497
Author(s):  
Daniel J. DeSalvo ◽  
Nudrat Noor ◽  
Cicilyn Xie ◽  
Sarah D. Corathers ◽  
Shideh Majidi ◽  
...  

Background: The benefits of Continuous Glucose Monitoring (CGM) on glycemic management have been demonstrated in numerous studies; however, widespread uptake remians limited. The aim of this study was to provide real-world evidence of patient attributes and clinical outcomes associated with CGM use across clinics in the U.S. based T1D Exchange Quality Improvement (T1DX-QI) Collaborative. Method: We examined electronic Health Record data from eight endocrinology clinics participating in the T1DX-QI Collaborative during the years 2017-2019. Results: Among 11,469 type 1 diabetes patients, 48% were CGM users. CGM use varied by race/ethnicity with Non-Hispanic Whites having higher rates of CGM use (50%) compared to Non-Hispanic Blacks (18%) or Hispanics (38%). Patients with private insurance were more likely to use CGM (57.2%) than those with public insurance (33.3%) including Medicaid or Medicare. CGM users had lower median HbA1c (7.7%) compared to nonusers (8.4%). Rates of diabetic ketoacidosis (DKA) and severe hypoglycemia were significantly higher in nonusers compared to CGM users. Conclusion: In this real-world study of patients in the T1DX-QI Collaborative, CGM users had better glycemic control and lower rates of DKA and severe hypoglycemia (SH) events, compared to nonusers; however, there were significant sociodemographic disparities in CGM use. Quality improvement and advocacy measures to promote widespread and equitable CGM uptake have the potential to improve clinical outcomes.


2021 ◽  
Vol 4 ◽  
pp. 87
Author(s):  
Paul M Ryan ◽  
Michael Zahradnik ◽  
Kristin J Konnyu ◽  
Tamara Rader ◽  
Michael Halasy ◽  
...  

Introduction: Optimal glycaemic control is often a challenge in children and adolescents with type 1 diabetes (T1D). Implementation of patient, clinician or organisation-targeted quality improvement (QI) strategies has been proven to be beneficial in terms of improving glycaemic outcomes in adults living with diabetes. This review aims to assess the effectiveness of such QI interventions in improving glycaemic control, care delivery, and screening rates in children and adolescents with T1D. Methods and analysis: MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL databases will be searched for relevant studies up to January 2021. Trial registries, ClinicalTrials.gov and ICTRP, will also be explored for any ongoing trials of relevance. We will include trials which examine QI strategies as defined by a modified version of the Cochrane Effective Practice and Organisation of Care 2015 Taxonomy in children (<18 years) with a diagnosis of T1D. The primary outcome to be assessed is glycated haemoglobin (HbA1c), although a range of secondary outcomes relating to clinical management, adverse events, healthcare engagement, screening rates and psychosocial parameters will also be assessed. Our primary intention is to generate a best-evidence narrative to summarise and synthesise the resulting studies. If a group of studies are deemed to be highly similar, then a meta-analysis using a random effects model will be considered. Cochrane Risk of Bias 1.0 tool will be applied for quality assessment. All screening, data extraction and quality assessment will be performed by two independent researchers. Dissemination: The results of this review will be disseminated through peer-reviewed publication in order to inform invested partners (e.g., Paediatric Endocrinologists) on the potential of QI strategies to improve glycaemic management and other related health outcomes in children with T1D, thereby guiding best practices in the outpatient management of the disorder. PROSPERO registration number: CRD42021233974 (28/02/2021).


Sign in / Sign up

Export Citation Format

Share Document